Sitagliptin versus placebo in the treatment of nonalcoholic fatty liver disease: A randomized controlled trial

BACKGROUND & AIMS: Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may improve alanine aminotransferase (ALT) and liver histology in nonalcoholic fatty liver disease (NAFLD) patients. We aimed to compare sitagliptin versus placebo's efficacy in reducing liver fat measured by...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Hepatol
Päätekijät: Cui, Jeffrey, Philo, Len, Nguyen, Phirum, Hofflich, Heather, Hernandez, Carolyn, Bettencourt, Ricki, Richards, Lisa, Salotti, Joanie, Bhatt, Archana, Hooker, Jonathan, Haufe, William, Hooker, Catherine, Brenner, David A, Sirlin, Claude B, Loomba, Rohit
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081213/
https://ncbi.nlm.nih.gov/pubmed/27151177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2016.04.021
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia